AnaptysBio (NASDAQ:ANAB) Shares Up 8.2%

AnaptysBio, Inc. (NASDAQ:ANAB) was up 8.2% on Friday . The stock traded as high as $20.52 and last traded at $20.42. Approximately 253,023 shares traded hands during trading, a decline of 19% from the average daily volume of 312,846 shares. The stock had previously closed at $18.87.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ANAB shares. Stifel Nicolaus started coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. BTIG Research began coverage on shares of AnaptysBio in a report on Monday, February 26th. They set a “buy” rating and a $55.00 price objective for the company. Wedbush raised shares of AnaptysBio from a “neutral” rating to an “outperform” rating and increased their price target for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. Leerink Partnrs reissued an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. Finally, Piper Sandler began coverage on shares of AnaptysBio in a research note on Friday, February 16th. They set an “overweight” rating and a $80.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.22.

AnaptysBio Price Performance

The stock has a market capitalization of $573.72 million, a P/E ratio of -3.45 and a beta of -0.30. The business’s 50 day simple moving average is $22.93 and its 200-day simple moving average is $20.58.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The firm had revenue of $9.01 million for the quarter, compared to analysts’ expectations of $3.28 million. Research analysts anticipate that AnaptysBio, Inc. will post -6.17 earnings per share for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other news, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now directly owns 3,240 shares of the company’s stock, valued at $81,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 157,005 shares of company stock valued at $3,586,199. 35.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of AnaptysBio during the first quarter worth $38,000. Fisher Asset Management LLC raised its holdings in shares of AnaptysBio by 0.7% during the fourth quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after acquiring an additional 500 shares during the period. Octagon Capital Advisors LP acquired a new stake in shares of AnaptysBio during the fourth quarter worth $2,570,000. Great Point Partners LLC raised its holdings in shares of AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after acquiring an additional 82,648 shares during the period. Finally, First Light Asset Management LLC raised its holdings in shares of AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.